People · Operator
Named in public records as an officer, director or promoter · active 2016–2023 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alveo Technologies Inc. | — | Biotechnology | Series C | $63.6M | $503.5M | 2016 |
| Techcyte, Inc. | — | Other Health Care | Series B | $29.3M | $64.5M | 2021 |
Michael Aicher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Aicher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 1 | 14 |
| Richard Smith | 1 | 11 |
| Nicholas Brathwaite | 1 | 9 |
| Michael Wolfgramm | 1 | 9 |
| Ralph Yarro | 1 | 4 |
| Lawrence Blatt | 1 | 3 |
| Ben Cahoon | 1 | 2 |
| Robin Steele | 1 | 2 |
| Yuh-Min Chiang | 1 | 1 |
| Ron Chiarello | 1 | 1 |
| Mohammed Salama | 1 | 1 |
| William Dorsey | 1 | 1 |
| Jay Tolley | 1 | 1 |
| Kent Gordon | 1 | 1 |
| Kyle Wilson | 1 | 1 |
| Ronald Chiarello | 1 | 1 |
| Julianne Averill | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.